嵌合抗原受体疗法在感染性疾病中的应用:聚焦侵袭性真菌感染
本综述基于PubMed文献,总结CAR疗法在感染性疾病中的证据,重点讨论侵袭性真菌感染。靶向真菌细胞壁β-葡聚糖和甘露聚糖的CAR构建体在临床前显示增强抗真菌活性,CAR-NK和CAR-巨噬细胞在IFI患者中展现初步临床可行性,但临床证据有限,制造复杂性和安全性问题制约转化。
要点
- CAR-T靶向β-葡聚糖和甘露聚糖在临床前对曲霉和念珠菌显示增强抗真菌活性。
- CAR-NK和CAR-巨噬细胞可能降低毒性并实现现货供应,已在IFI患者中显示初步可行性。
- CAR疗法临床证据有限,制造复杂、抗原异质性和安全性问题限制其临床转化。
核心结论
- CAR免疫疗法是免疫抑制患者严重感染,尤其是难治或多重耐药感染的新型潜在变革性策略。
研究设计与样本
- 叙述性综述,通过PubMed检索评估CAR方法在真菌、病毒和部分细菌感染中的临床前和临床研究。
主要发现
- 靶向β-葡聚糖和甘露聚糖的CAR构建体在临床前显示增强抗真菌活性和免疫激活,尤其针对曲霉和念珠菌。
- CAR-NK和CAR-巨噬细胞在IFI患者中显示初步临床可行性。
- CAR方法对病毒和部分细菌病原体也显示活性,但临床应用仍主要为探索性。
临床怎么用
- CAR免疫疗法目前仍处于探索阶段,不推荐作为常规临床实践。
- 对于免疫抑制患者难治性或多重耐药感染,可考虑在临床研究框架下评估CAR疗法。
局限性
- 制造复杂且延迟可得。
- 安全性问题。
- 抗原异质性。
- 临床证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infections remain a major cause of morbidity and mortality among immunocompromised patients, particularly in the context of invasive fungal infections (IFIs), where outcomes are strongly dependent on host immune status. Despite advances in antifungal therapy, mortality remains high, highlighting the need for novel immunotherapeutic strategies. OBJECTIVES: This review aims to summarize current evidence on chimeric antigen receptor (CAR)-based therapies for infectious diseases, with a particular focus on IFIs, and to discuss their potential role, limitations, and future perspectives. SOURCES: A narrative review of the literature was conducted using PubMed, focusing on preclinical and clinical studies evaluating CAR-based approaches in fungal, viral, and selected bacterial infections. Relevant references were identified from database searches and cross-referencing of key articles. CONTENT: CAR-engineered immune cells, particularly CAR-T cells, represent a promising strategy to restore pathogen-specific immunity in immunocompromised hosts. In IFIs, targeting conserved fungal cell wall components such as β-glucans and mannans has shown encouraging preclinical results, with different CAR constructs demonstrating enhanced antifungal activity and immune activation, particularly against Aspergillus and Candida species. Alternative platforms, including CAR-natural killer cells and CAR macrophages, may offer advantages such as reduced toxicity and off-the-shelf availability, and have shown preliminary clinical feasibility in a patient with IFI. Although CAR-based approaches have also demonstrated activity against viral and selected bacterial pathogens, their clinical application remains largely exploratory. Several challenges limit translation into clinical practice, including complex manufacturing, delayed availability, safety concerns, antigen heterogeneity, and limited clinical evidence. IMPLICATIONS: CAR-based immunotherapy represents a novel and potentially transformative approach for the management of severe infections in immunocompromised patients, particularly those with refractory or multidrug-resistant disease. Advances in manufacturing, target selection, and combination strategies will be essential to overcome current limitations. Further clinical studies are needed to define their safety, efficacy, and positioning within existing therapeutic frameworks.
引用
- Bracke C, Grafia I, Puerta-Alcalde P, et al. Chimeric antigen receptor therapy in infectious diseases: emerging applications with a focus on invasive fungal infections. Clin Microbiol Infect. 2026. PMID: 42607832. doi:10.1016/j.cmi.2026.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。